Cincinnati, Ohio (June 6, 2017)

M Pharmaceutical Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the “Company” or “M Pharma”), is pleased to announce that it has recently received official USPTO “Notice Of Allowance” for the US Trademark of EXTRINSA the Company’s solutionfor Female Sexual Dysfunction (FSD).

“We are excited to receive this additional USPTO trademark protection for our FSD product. At this critical stage in the development of Extrinsa, it is prudent and necessary to protect not only our technology, but our shareholder’s investment dollars as well,” said Gary Thompson, President & CEO of M Pharmaceutical Inc.

“Our staff at M Pharma is working closely with Camargo Pharmaceutical Services based in Cincinnati, Ohio to strengthen and expedite the process to bring Extrinsa to market, benefitting millions of women suffering from Female Sexual Dysfunction,” added Mr. Thompson.

About Extrinsa

Unlike the other two drugs approved by the US FDA to treat FSD, the company’s topical drug product, Extrinsa, would focus on women with orgasm and arousal difficulties. Valeant’s Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA imposed prescription and marketing restrictions. Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions. M Pharma’s Extrinsa treatment is topical, local and non-systemic, with daily and on demand use, while being non-hormonal and not a central nervous system drug. Based on these core attributes, the safety profiles of the API and excipients in the drug product, and the dosage and delivery form, the company anticipates Extrinsa to be extremely well-tolerated and highly effective for many women suffering from FSD and has a great likelihood of ultimate approval by the FDA.

About Callitas Therapeutics

Formerly M Pharmaceutical Inc., Callitas Therapeutics was formed in early 2015, is a clinical-stage company developing innovative technologies for obesity, weight management and Female Health & Wellness.  In addition to its recent acquisitions of C-103, a reformulation of orlistat from Chelatexx, LLC and assets from 40J’s LLC including Extrinsa, the Company is scheduled to launch their FDA cleared fertility product branded as ToConceive in July of this year.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:
Investor Relations
Phone: +1 (859) 868-3131

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.


As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.


  • 1.859.868.3131
  • investors@callitas.com

  • 187 Pavilion Parkway
    Suite 200
    Newport, Kentucky 41071


  • pressroom@callitas.com